

Epidemiological, clinical and radiological profile of patients hospitalized for COVID-19 at the Epidemic Treatment Centre of the Fann hospital, Dakar during the third and fourth waves

ABSTRACT

Aims: To describe the epidemiological, clinico-biological and radiological aspects of patients hospitalized for COVID-19 infection at the Fann Epidemics Treatment Center (ETC).

Methodology: Cross-sectional study in Fann hospital, between July 2021 and March 2022. We included all patients hospitalized for COVID-19 infection on the basis of epidemiological, clinical and CT scanographic evidence associated with a positive RT-PCR or Ag RDT. The data were entered into Excel and analysed using R software. Qualitative variables were expressed as absolute and relative frequencies. Quantitative variables were described by the average accompanied by its standard deviation or the median associated with the extremes according to their distribution.

Results: A total of 248 patients were enrolled during the study period. The average age was 61.7 ±15.2 years. Of the 248 patients, 110 were women (44.4%). High blood pressure was the most frequent comorbidity and was found in 89 patients (35.89%), followed by diabetes (21.7%) and obesity (7.26%) respectively. Three quarters (76.6%) of our patients had not been vaccinated against COVID-19. Dyspnoea was the most frequently encountered clinical symptoms (77%). More than a third of patients (39%) had extra-respiratory symptoms. A total of 109 patients underwent d-dimer testing, of whom 80 (73.4%) had levels ≥ 500ng/ml. One hundred and eighty-two patients (73.4%) had undergone thoracic CT or CT angio. And among them, 71.9% had ground-glass lesions, and half (50%) had severe to critical lesions. In our study, 52 patients died, representing a case-fatality rate of 21%.

Conclusion: Our study population consisted mainly of elderly subjects, most of whom had not been vaccinated against COVID-19 and had one or more comorbidities, the most representative of which were high blood pressure, diabetes and heart diseases. In this population, the mortality rate of COVID-19 was significant, approximately one in four patients.

Keywords: COVID-19, Profile, Fann

1. INTRODUCTION

Coronaviruses form a family comprising a large number of viruses that can cause a wide range of diseases in humans, from the common cold to severe acute respiratory distress syndrome [1]. COVID-19 (Coronavirus Infectious Disease 2019) is an emerging contagious zoonotic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The pandemic started in Wuhan, China and was first reported to the World Health Organization (WHO) in December 2019 [2]. It was declared a public health emergency of international concern (PHEIC) on 30 January 2020, and a pandemic on 11 March 2020 [1]. Existing data imply that COVID-19 is easily transmitted by person-to-person contact, probably via respiratory droplets, and can be transmitted by infected people who have no or mild symptoms, leading to its rapid spread. Based on initial data, 15% of infected people develop a severe form of the disease, with a case-fatality rate of around 3%, but higher in the elderly and those with co-morbidities, especially cardiovascular, and metabolic [3]. As of 20 July 2021, 191,968,747 positive cases had been reported and 4,121,955 deaths notified, with very significant socio-economic repercussions [4]. In the face of rampant globalisation, Africa, and Senegal in particular, have not escaped this devastating pandemic. Even though Africa appears to be less affected, with 6,267,776 positive cases, or 3.26% of cases worldwide, and 158,697 deaths recorded as of 20 July 2021 [4]. In Senegal, since the first case was recorded on 2 March 2020, the monthly number of positive cases, and deaths linked to COVID-19 has been steadily increasing [5]. The geographical distribution of the number of cases is uneven across the country. As of 20 July 2021, the Dakar region was the epicenter of the pandemic, accounting for more than 67.72% of national cases. It is followed by the regions of Thiés and Diourbel, which accounted for 10.79% and 3.84% of national cases respectively [6]. It is in this context that we conducted this study, the aim of which was to describe the epidemiological, clinico-biological and radiological aspects of patients hospitalised for COVID-19 infection at the Fann ETC (Epidemics Treatment Centre).

2. METHODOLOGY

2.1. TYPE AND PERIOD OF STUDY

This was a retrospective, cross-sectional, descriptive study conducted over a period of 09 months from 01 July 2021 to 31 March 2022.

2.2. STUDY POPULATION

Our work focused on all patients with COVID-19 hospitalized at the Epidemics Treatment Centre of Fann hospital during the 3rd and 4th waves. We performed an exhaustive sampling and included all patients hospitalized for COVID-19 infection on the basis of epidemiological, clinical and CT scanographic evidence associated with a positive RT-PCR or Ag RDT.

2.3. DEFINITION OF VARIABLES

- Hyperleukocytosis was defined as a white blood cell count higher than or equal to 12,000 cells/mm³.
- Thrombocytopenia was defined as a platelet rate of less than 150,000 cells/mm³.
- Elevated C-reactive protein was defined as a level higher than or equal to 6mg/l
- And for PCT (procalcitonin) a level higher than 0.5ng/ml.
- D-dimer levels were considered elevated when they were higher than 500ng/ml.

- Creatinine was considered elevated when its level was higher than 13mg/l.
- The extent of CT lesions was assessed according to the definition of the French Society of Radiology, with several stages including minimal (<10%), moderate (10-25%), significant (26-50%), severe (51-75%) and critical (>75%).

2.4. DATA COLLECTION

Data were collected from patients' medical records and laboratory data using a Microsoft Excel Workbook (.xlsx) input mask. The following parameters were collected epidemiological characteristics (age, sex, occupation, address, marital status, comorbidities, anti-COVID-19 vaccination status, type of vaccine) clinical characteristics (time between anti-COVID-19 vaccination and onset of infection, respiratory symptoms, extra-respiratory symptoms (neurological, musculoskeletal, digestive, cardiovascular, uronephrological), paraclinical characteristics (blood count, C-reactive protein, procalcitonin, transaminases, creatininemia, D-dimer and thoracic CT or CT angio) therapeutic characteristics (treatment received before admission to the ETC (Epidemics Treatment Centre), treatment received during hospitalisation at the ETC) evolutionary characteristics (time of hospitalisation, number of patients who died, recovered or were transferred).

2.5. DATA ENTRY AND ANALYSIS

The data were entered into Excel and analysed using version 4.1.0 of the R software. Qualitative variables were expressed as absolute and relative frequencies. Quantitative variables were described by the average accompanied by its standard deviation or the median associated with the extremes according to their distribution.

3. RESULTS

3.1. EPIDEMIOLOGICAL ASPECTS

A total of 248 patients were enrolled during the study period. The average age was 61.7 ±15.2 years and the most representative age group was 60 years and over. Of the 248 patients, 110 were women (44.4%), with a sex ratio (M/F) of 1.25. Over a third of our patients (36.7%) had no occupation. One hundred and forty-two patients (78%) were married. More than half of our patients (57.5%) lived in Dakar. High blood pressure was the most frequent comorbidity and was found in 89 patients (35.89%), followed by diabetes (21.7%) and obesity (7.26%) respectively. Among our 248 patients, 58 (23.4%) had been vaccinated against COVID-19 versus 190 (76.6%) no vaccinated. Those vaccinated were mainly Sinopharm (34%), Astrazeneca (28%), Johnson and Johnson and Pfizer. Two hundred and fifteen (86.7%) of the patients had been hospitalized in another facility prior to their admission to the Fann ETC (Table 1).

Table 1: Distribution of patients according to epidemiological characteristics (ETC of Fann, July 2021-March 2022), N=248

Characteristics	Absolute frequency (n)	Relative frequency (%)
Sociodemographic		
Sex		

Men	138	55.6
Women	110	44.4
Age		
< 20 ans	02	1.2
[20-40 ans [19	7.7
[40-60 ans [84	33.9
≥ 60 ans	143	57.3
COVID-19 Vaccination		
Yes	58	23.4
No	190	76.6
Type of COVID-19 vaccine received		
Sinopharm	20	34.0
Astrazeneca	16	28.0
Johnson-Johnson	07	12.0
Pfizer	01	2.0
Not specified	14	24.0
Comorbidities		
Arterial hypertension	89	35.9
Diabete	55	22.2
Obesity	18	7.2
Cardiopathy	15	6.0
Smoking	11	4.4
Cerebrovascular accident	7	2.8
Tuberculosis	6	2.4
Dyslipidemia	5	2.0
COPD*	2	0.8
HIV* Infection	1	0.4
Dysthyroidism	1	0.4
Chronic kidney disease	1	0.4
Solid tumors	1	0.4
Ethylism	3	0.1

*: COPD (Chronic obstructive pulmonary disease); HIV (Human immunodeficiency virus)

3.2. CLINICAL ASPECTS

Dyspnoea was the most frequently encountered clinical symptoms (77% of patients), followed by cough and chest pain (58.5% and 24.6% respectively). More than a third of patients (39%) had extra-respiratory symptoms (**Figure 1**). Of the 58 patients vaccinated against COVID-19, 38 were up-to-date versus 20 who were not. The mean time between onset of COVID-19 disease and vaccination was 5.09 ± 4.63 weeks [1-13 weeks].




Figure 1: Distribution of patients by clinical symptoms, ETC of Fann (july 2021-march 2022, N=248)

3.3. PARACLINICAL ASPECTS

Sixty-two patients (44%) had hyperleukocytosis on blood count. One hundred and thirty-three patients (133/144) or 92.4% had a C-reactive protein ≥ 6 mg/l. Of 87 patients who had a procalcitonin assay, 30 (34.9%) had an elevated level. Thirty patients (14.1%) had hepatic cytolysis, and 25 had creatinine levels ≥ 13 mg/l. A total of 109 patients underwent d-dimer testing, of whom 80 (73.4%) had levels ≥ 500 ng/ml. One hundred and eighty-two patients (73.4%) had undergone thoracic CT or CT angio. And among them, 71.9% had ground-glass lesions, and half (50%) had severe to critical lesions (**Table 2**).

Table 2: Distribution of patients according to type and extent of lesions on thoracic CT (ETC of Fann, July 2021-March 2022)

Type of lesions on chest CT (N=182)	Absolute frequency (n)	Relative frequency (%)
Ground-glass	131	72.0
Infiltrates	7	3.9

Pleuresis	4	2.2
Condensations	4	2.2
Fibrosis	3	1.7
Not specified	27	14.9
Normal	06	3.3
Extent of CT lesions		
(N=176)		
Critical	38	21.6
Severe	50	28.4
Important	11	6.3
Moderate	38	21.6
Minimal	23	13
Not specified	16	9.1

3.4. THERAPEUTIC ASPECTS

Almost all our patients (97.8%) had received preventive or curative anticoagulation combined with corticosteroid therapy (93.6%). In addition, 223 patients (89.9%) had been treated with non-specific antibiotics, mainly third-generation cephalosporins and macrolides.

3.5. EVOLUTIONARY ASPECTS

The average duration of hospitalisation was 7.49 ± 6.04 days [0-38 days]. In our study, 52 patients died, representing a case-fatality rate of 21%. A further 33 patients (13.3%) were transferred to intensive care.

3.6. DISCUSSION

COVID-19 infection is a truly global public health problem, with many mysteries still to be unravelled. The aim of this study is to describe the profile of patients hospitalised for COVID-19 at the CHNU Fann epidemic treatment centre, during the 3rd and 4th waves in Senegal.

The average age of our patients was 61.7 ± 15.2 years, and the most representative age group was 60 years and over. These data are similar to those found elsewhere, particularly in Italy [7], Algeria [8] and China [9], where the average age was similar to ours (over 50 years). On the other hand, Mwana et al [10] in Congo and Haidara et al [11] in Mali found a younger average age of 46 and 47 respectively. This could be due to the fact that, although the African population is relatively young, **COVID-19** infection mainly affects older people. Indeed, due to the senescence of the immune system, the latter present a greater susceptibility to infections, in this case **COVID-19**, compared with young adults.

In line with the literature [12, 13, 14, 8, 15], high blood pressure was the most common comorbidity (35.9%), followed by diabetes (22.2%) and obesity (7.26%) respectively. These data corroborate national data [16, 17, 18]. This could be explained by the fact that patients with one or more co-

morbidities are more likely to develop symptomatic or even severe forms of COVID-19, especially if they are not well controlled, hence their hospitalisation.

Also, in relation to vaccination, 76.6% of our patients had not been vaccinated against COVID-19. Although vaccination is supposed to protect against symptomatic or even severe forms of the disease, data in the literature [19, 20, 21] show a decrease in the efficacy of COVID-19 vaccines in elderly patients and those with one or more comorbidities and/or infection with alpha and delta variants, the main explanatory factor being a decrease in the level of neutralising antibodies in these patients. Our study population had almost all these factors, i.e. advanced age and one or more comorbidities in more than a quarter of them. In addition, our study period corresponded to the 3rd and 4th waves in Senegal, during which the main circulating variants were alpha and delta.

Two hundred and fifteen (86.7%) of the patients had been hospitalized in another facility prior to their admission to the Fann ETC. It could be due to the fact that the Fann ETC is one of the reference facilities for the management of COVID-19 cases in Senegal, and consequently most of the country's severe cases are admitted there, thus explaining the significance of the high percentage of patients previously hospitalized in another facility.

Clinically, respiratory symptoms were at the forefront of the clinical picture. These results are similar to those found in the literature [8, 9, 10, 11, 12, 13, 14, 22, 23] and once again demonstrate the respiratory tropism of SARS-CoV-2. In addition, more than a third of our patients (39%) had extra-pulmonary symptoms such as encephalitis, diarrhoea and impaired kidney function. This systemic nature of COVID-19 infection has also been found in other studies, particularly those by Ravindra et al [24], B.Long et al [25], Zhou et al [22] and Klok et al [26]. This is easily explained by the pathophysiology of SARS-CoV-2 infection with viral invasion via host ACE2 receptors. Several cells such as the small intestine, thyroid, testicles, adipose tissue, bladder and vascular endothelium express these ACE2 receptors. This sustains widespread pulmonary inflammation and multiple organ damage. This could also explain the positivity or even increase in D-dimer levels during Sars-CoV-2 infection. In fact, of the 109 patients who underwent D-dimer testing, 80 (73.4%) had elevated D-dimer levels. The same results have been found elsewhere [22, 27, 28].

One hundred and eighty-two patients (73.4%) had undergone thoracic CT or CT angio. And among them, 71.9% had ground-glass lesions, and half (50%) had severe to critical lesions. The predominance of lesions with a ground-glass appearance found in our cohort is in line with the data in the literature [22, 28]. And the severity of the scanographic lesions could be linked to the advanced age of our patients and the presence of co-morbidities that weaken the immune system. Similarly, the delay in consultation and the absence of vaccination against COVID-19 (76% of our patients) could also explain the occurrence of these severe forms. Similar results have been found in the literature, particularly by Diop et al [29], Kalidou et al [18] and Kaeuffer et al [30].

Nearly 90% of our patients were treated with non-specific antibiotics, mainly third-generation cephalosporins and macrolides. This could be explained by the frequency of bacterial superinfections in severe forms of COVID-19, making it necessary to start broad-spectrum probabilistic treatment in order to target as many pathogens as possible while awaiting the results of confirmatory paraclinical tests, and to limit the number of deaths.

The case fatality rate in our series was 21%, which is similar to that found in Korea [31] and Tunisia [32]. This could be linked to the advanced age of our patients, but also to the presence of co-morbidities such as high blood pressure, diabetes, obesity and heart diseases. On the other hand, Diop et al [29] and Kalidou et al [18], in studies conducted in Dakar and Ziguinchor respectively, found a lower-case fatality rate (4.2 to 7.7%). This difference could be due to the fact that the Fann ETC is one of the reference facilities for the management of COVID-19 cases in

Senegal, and consequently most of the country's severe cases are admitted there, thus explaining this non-negligible case-fatality rate compared with other ETCs.

4. CONCLUSION

Our study population consisted mainly of elderly subjects, most of whom had not been vaccinated against COVID-19 and had one or more co-morbidities, the most representative of which were high blood pressure, diabetes, and heart diseases. One hundred and eighty-two patients (73.4%) had undergone thoracic CT or CT angio. And among them, 71.9% had ground-glass lesions, and half (50%) had severe to critical lesions. In addition, the mortality rate of COVID-19 was significant, approximately one in four patients. A study of the factors associated with death would provide a better understanding, and could even help to improve patient care.

Consent

As per international standards or university standards, patient(s) written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

As per international standard or university standard written ethical approval has been collected and preserved by the authors.

REFERENCES

1. Ren LL, Wang YM, Wu ZQ, Xiang ZC, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. *Chin Med J (Engl)*. May 5, 2020;133(9):1015- 24.
2. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. *Nat Rev Microbiol*. March 2019;17(3):181- 92. doi:10.1038/s41579-018-0118-9.
3. WHO: Africa Regional Office
4. WHO. Q&A: Similarities and differences between COVID-19 and the flu <https://www.who.int/en/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19-similarities-and-differences-with-influenza>. (Accessed January 15, 2022).
5. WHO. Coronavirus disease (COVID-19). Situation Report (online). 2020 May 9, No. 110. Availability on the Internet: <https://apps.who.int/iris/handle/10665/332065> (accessed January 17, 2022)
6. WHO. Overview of Public Health and Social Measures in the context of COVID-19 <https://www.who.int/publications/i/item/overview-of-public-health-and-social-measures-in-the-context-of-covid-19>. (Consult February 25, 2022)
7. Onder G, Rezza G, Brusaferro S (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. *JAMA* 2020 323:1775-1776. doi:10.1001/jama.2020.4683.
8. Ketfi A, Chabati O, Chemali S, Mahjoub M, Gharnaout M, Touahri R, et al. Clinical, biological and radiological profile of Algerian patients hospitalized for COVID-19: preliminary data. *Pan African Medical Journal*.2020;35(2):77. doi:10.11604/pamj.supp.2 020.35.2.23807.

9. Wu J, Wu X, Zeng W, Gui D, Frang Z, Chen L, et al. Chest CT findings in patients with Coronavirus diseasedsz 2019 and its relationship with clinical features. *Invest Radiol*.2020; 55(5):257-61.
10. Mwana-Yile H, Kampanga G, Mathe H, Diyoyo P, Ngalala A, Kilandamoko C, et al. Profile of COVID-19 positive patients admitted to the Sino-Congolese Friendship Hospital of N'djili from March 10 to June 30, 2020, Kinshasa, Democratic Republic of Congo. *Rev Mali Infect Microbiol* 16:39-46. 15. doi: <https://doi.org/10.53597/remim.v16i1.1759>
11. Mali Haïdara DBS, Traore M, Cissouma A, Mariko ML, Kante M, Touré L, et al. Covid-19: Epidemio-clinical, therapeutic and evolutionary aspects of the Patients treated. Case of Sikasso Hospital.*Rev Mali Infect Microbiol* 2022, 17 (1):17-23
12. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. *JAMA Intern Med*. 2020;180(7):934-43. doi: 10.1001/jamainternmed.2020.0994
13. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem AM. Evidence for camel-to-human transmission of MERS coronavirus. *N Engl J Med*2014; 370(26):2499–505
14. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, Lee M. Characteristics outcomes of 21 critically ill patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. *Lancet*.2020; 395(10223):507-13.
15. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*.2020; 395(10223):507-13.
16. Republic of Senegal, Ministry of Health and Social Action. The Covid19 review in Senegal: Facts & Figures [online]. August 5, 2020, No. 10, [consulted on JUNE 10, 2022]. Availability on the Internet: <https://sante.gouv.sn/Pr%C3%A9sentation/le-coronavirus-est-toujours-l%C3%A0-ciiquez-ici-pour-acc%C3%A9der-%C3%A0-la-revue-weekly-health%C3%A9>
17. Diarra M, Barry A, Dia N, Diop M, Sonko I, Sagne S, et al. First wave COVID-19 pandemic in Senegal: Epidemiological and clinical characteristics. *PLOS ONE*, 2022;17(9): e0274783. <https://doi.org/10.1371/journal.pone.0274783>
18. Kalilou Diallo, Mame Aissé Thioubou, Bruce Shinga Wembulua, Yaya Kane, Mame Ngoné Coly, Abdou Badiane, et al. COVID-19: Experience of the Epidemic Treatment Center in Ziguinchor, Southern Region of Senegal. *J Infect Dis Epidemiol* 2021, 7:216
19. Nick Andrews, Julia Stowe, Freja Kirsebom, Samuel Toffa, Ruchira Sachdeva, Charlotte Gower, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. *Nature Medicine*, April 2022;28:831–837
20. Matan Levine-Tiefenbrun, Idan Yelin, Hillel Alapi, Rachel Katz, Esma Herzel, Jacob Kuint, et al. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and boost with BNT162b2. *Nature Medicine*, December 2021;27:2108–2110
21. Koen B. Pouwels, Emma Pritchard, Philippa C. Matthews, Nicole Stoesser, David W. Eyre, Karina-Doris Vihta, et al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK *Nature Medicine*, December 2021;27:2127–2135
22. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adults in patients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395(10229):1054–62
23. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 hospitalized patients with 2019 novel Coronavirus infected pneumonia in Wuhan, China. *JAMA* 2020;323(11):1061-9.
24. Vijay M Ravindra, Ramesh Grandhi, Alen Délic, Samuel Hohman, Ernie Shippey, David Tirschwell, et al. Impact of COVID-19 on hospitalization, treatment, and outcomes of intracerebral and subarachnoid hemorrhage in the United States . *PLoS One*, April 2021;16(4):e0248728. doi: 10.1371/journal.pone.0248728. eCollection 2021
25. Brit Long MD, William J. Brady MD, Alex Koyfman MD, Michael Gottlieb MD. Cardiovascular complications in COVID-19. *The American Journal of Emergency Medicine*, July 2020;38 (7):1504-1507. doi: 10.1016/j.ajem.2020.04.048.
26. FA Klok, MJHA Kruij, N.JM van der Meer, M.S. Arbous, D.AMPJ Gommers, K.M. Kant, et al. Incidence of thrombotic complications in critically ill intensive care patients with COVID-19. *Thromb Res*. Jul 2020; 191:145–147

27. Guan W., Ni Z., Hu Y., Liang W., Ou C., He J, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Engl J Med.* 2020 doi:10.1056/NEJMoa2002032. NEJMoa2002032.
28. Chen T., Wu D., Chen H., Yan W., Yang D., Chen G., et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ.* 2020:368. doi:10.1136/bmj.m1091.
29. Diop M., Ba P.S., Lo M., Essomba N., Fall B., Sarr M.N., et al. Factors Associated with Severe COVID-19 in an Epidemic Treatment Center at Dakar. *J Infect Dis Epidemiol.* 2021;7:203. doi.org/10.23937/2474-3658/1510203
30. Kaeuffer C, Le hyaric C, Fabacher T, Mootien J, Ruch Y, Zhu Y, et al. Clinical characteristics and risk factors associated with severe forms of COVID-19: Prospective multicenter analysis of 1045 cases. *Med Mal Infect* 50:S27.
31. Shim E, Tariq A, Choi W, Lee y, Chowell G. Transmission potential and severity of COVID-19 in South Korea. *Int J Infect Dis* 2020;93:339-44
<http://dx.doi.org/10.1016/j.ijid.2020.03.031>.
32. Louhaichi S, Allouche A, Baili H, Jrad S, Radhouani A, Greb D, et al. Features of patients with 2019 novel coronavirus admitted in a pneumology department: The first retrospective Tunisian case series. *Tunis Med.* 2020; 98(4):261-5.